Oncotarget

Research Papers:

Investigation of Cytotoxic T-lymphocyte antigen-4 polymorphisms in non-small cell lung cancer: a case-control study

Shuchen Chen, Yafeng Wang, Yu Chen, Jihong Lin, Chao Liu, Mingqiang Kang and Weifeng Tang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:76634-76643. https://doi.org/10.18632/oncotarget.20638

Metrics: PDF 1173 views  |   HTML 1935 views  |   ?  


Abstract

Shuchen Chen1, Yafeng Wang2, Yu Chen3, Jihong Lin1, Chao Liu4, Mingqiang Kang1,5,6 and Weifeng Tang1

1Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China

2Department of Cardiology, The People's Hospital of Xishuangbanna Dai Autonomous Prefecture, Jinghong, Yunnan Province, China

3Department of Medical Oncology, Fujian Cancer Hospital, Fujian Medical University Cancer Hospital, Fuzhou, Fujian Province, China

4Department of Cardiothoracic Surgery, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, Jiangsu Province, China

5Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian Province, China

6Fujian Key Laboratory of Tumor Microbiology, Fujian Medical University, Fuzhou, Fujian Province, China

Correspondence to:

Weifeng Tang, email: [email protected]

Mingqiang Kang, email: [email protected]

Keywords: CTLA-4, polymorphism, non-small cell lung cancer, immune

Received: May 25, 2017     Accepted: August 17, 2017     Published: September 04, 2017

ABSTRACT

The objective of this case-control study was to extensively explore the relationship of Cytotoxic T-lymphocyte antigen-4 (CTLA-4) tagging polymorphisms with susceptibility to non-small-cell lung cancer (NSCLC). We recruited 521 sporadic NSCLC cases and 1,030 non-cancer controls. The genotypes of CTLA-4 rs16840252 C>T, rs231775 G>A, rs3087243 G>A and rs733618 T>C polymorphisms were evaluated using a custom-by-design 48-Plex SNPscan Kit. Our findings revealed there was no statistically significant difference in CTLA-4 genotypes distribution among NSCLC patients and non-cancer controls. Similar findings were observed in the logistic regression analyses. However, the stratified analyses suggested CTLA-4 rs733618 vatiants were correlated with the development of NSCLC in ≥ 60 years subgroup (TC vs. TT: adjusted OR = 1.45, 95% CI = 1.04–2.02, P = 0.030) and even drinking subgroup (TC vs. TT: adjusted OR = 2.27, 95% CI = 1.11–4.60, P = 0.024 and TC/CC vs. TT: adjusted OR = 2.26, 95% CI = 1.15–4.43, P = 0.018). In conclusion, the present case-control study highlights that the CTLA-4 rs733618 T>C polymorphism was associated with the development of NSCLC in ≥ 60 years and even drinking subgroups. A fine-mapping study with functional assessment is necessary to confirm or refute our findings.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20638